臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"chuang w l"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 91-115 of 218 (9 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-09-04T05:16:52Z	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?	Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏	2021-09-04T05:16:49Z	Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping	JIA-HORNG KAO; Lin C.-Y.; Chuang W.-L.; Cheng Y.-Y.; Hu J.-Y.; Liang W.-K.; Friebe P.; Palmer S.; Huang C.-S.
臺大學術典藏	2021-09-04T05:16:48Z	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium	Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; Liu C.-H.; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏	2021-09-04T05:16:47Z	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation	Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Kadir Dokmeci A.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Ooka Y.; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏	2021-09-04T05:16:42Z	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions	Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO; Hsu S.-J.; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:39Z	Modelling NAFLD disease burden in four Asian regions—2019-2030	Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H.
臺大學術典藏	2021-09-04T05:16:36Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:35Z	Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply	Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H.
臺大學術典藏	2021-09-04T05:16:34Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:31Z	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:26Z	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis	Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y.
臺大學術典藏	2021-09-04T05:16:24Z	Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication	Ogawa E.; Toyoda H.; Iio E.; Jun D.W.; Huang C.-F.; Enomoto M.; Hsu Y.-C.; Haga H.; Iwane S.; Wong G.; Lee D.H.; Tada T.; Liu C.-H.; Chuang W.-L.; Hayashi J.; Cheung R.; Yasuda S.; Tseng C.-H.; Takahashi H.; Tran S.; Yeo Y.H.; Henry L.; Barnett S.D.; Nomura H.; Nakamuta M.; Dai C.-Y.; Huang J.-F.; Yang H.-I.; Lee M.-H.; Jun M.J.; JIA-HORNG KAO; Eguchi Y.; Ueno Y.; Tamori A.; Furusyo N.; Yu M.-L.; Tanaka Y.; Nguyen M.H.; Ahn S.B.; Azuma K.; Dohmen K.; Jeong J.Y.; Jung J.H.; Kajiwara E.; Kato M.; Kawano A.; Koyanagi T.; Ooho A.; Park S.H.; Satoh T.; Shimoda S.; Song D.S.; Takahashi K.; Yeh M.-L.; Yoon E.L.; Real-World Evidence from the Asia Liver Consortium Investigators
臺大學術典藏	2021-09-04T05:16:21Z	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Liu C.-J.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:16Z	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan	Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L.
臺大學術典藏	2021-07-03T03:35:18Z	Genetic predisposition of responsiveness to therapy for chronic hepatitis C	Hwang Y.; Chen E.Y.; Gu Z.J.; Chuang W.-L.; Yu M.-L.; Lai M.-Y.; Chao Y.-C.; Lee C.-M.; Wang J.-H.; Dai C.-Y.; Bey M.S.-J.; Liao Y.-T.; PEI-JER CHEN; Chen D.-S.
臺大學術典藏	2021-07-03T03:35:09Z	Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan	Sullivan S.D.; Veenstra D.L.; PEI-JER CHEN; Chang T.-T.; Chuang W.-L.; Tsai C.; Patel K.
臺大學術典藏	2021-07-03T03:34:42Z	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses	Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S.
臺大學術典藏	2021-07-03T03:34:39Z	Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses	Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Chen D.-S.
臺大學術典藏	2021-07-03T03:34:21Z	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion	Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:34:20Z	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up	Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-07-03T03:34:14Z	Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-07-03T03:34:05Z	Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection	Colvin R.A.; Tanwandee T.; Piratvisuth T.; Thongsawat S.; Hui A.J.; Zhang H.; Ren H.; PEI-JER CHEN; Chuang W.-L.; Sobhonslidsuk A.; Li R.; Qi Y.; Praestgaard J.; Han Y.; Xu J.; Stein D.S.; Chien R.-N.; Flisiak R.; Jablkowski M.; Liaw Y.-F.; Sung J.J.-Y.
臺大學術典藏	2021-07-03T03:33:59Z	Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-07-03T03:33:58Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:56Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.

Showing items 91-115 of 218 (9 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 51901611 Online Users : 1026 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library